Abstracts tagged "prognostic factors"

Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 0645 • ACR Convergence 2023
Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Oyvind Midtvedt¹, Carina Mihai⁶, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 2301 • ACR Convergence 2023
Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years
Shuzo Sato¹, Shuhei Yoshida¹, Yuya Sumichika¹, Kenji Saito¹, Haruki Matsumoto¹, Jumpei Temmoku¹, Yuya Fujita¹, Naoki Matsuoka¹, Tomoyuki Asano¹ and KIYOSHI MIGITA², ¹Fukushima Medical University, Fukushima, Japan, ²Department of Rheumatology Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: SLE patients often experience relapse in the course of treatment, in spite of the progress of therapeutic strategy in SLE. The purpose of this…
Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa-Parra¹, Andrew Hanson², Alain Sanchez-Rodriguez³, Jose Meade-Aguilar¹, Cynthia Crowson³ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
enrico De Lorenzis¹, Francesco Del Galdo², gerlando Natalello¹, Stefano Di Donato², lucrezia verardi¹, Vishal Kakkar², pier giacomo Cerasuolo¹, Francesco Varone³, Luca Richeldi³, Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Luis Vega Sevilla¹, Oscar E. Alvarez-González², Janett Riega-Torres³, Cassandra Michele Skinner-Taylor³, Diana Carolina Rubio Torres⁴, Lucio Vera Cabrera⁵, Dionicio A. Galarza-Delgado⁶, Jesus Alberto Cardenas-De la Garza⁷, Rodrigo J. Castillo-de la Garza⁵, Mario Alberto Aguilera Valenciano⁵, wendy Escalante⁵ and Hector Guerra⁸, ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico, ⁷Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁸Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
Abstract Number: 036 • 2023 Pediatric Rheumatology Symposium
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Germana Nardini¹, Claudia Bracaglia², Denise Pires Marafon¹, Emanuela Sacco³, Arianna De Matteis¹, Ivan Caiello¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Manuela Pardeo², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Fondazione Casa Sollievo della Sofferenza, Pediatria, San Giovanni Rotondo, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare autoinflammatory disease of unknown etiology. Several uncontrolled studies showed that early treatment with anakinra is associated…
Abstract Number: 0532 • ACR Convergence 2022
Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustainable Remission: Results from the Canadian Early Arthritis Cohort Study
orit schieir¹, Susan Bartlett², Marie-France Valois¹, Glen Hazlewood³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, diane tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹McGill University, Montréal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Centre of Arthritis Excellence (CArE), Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²The Canadian Early Arthritis Cohort (CATCH), Bowmanville, ON, Canada
Background/Purpose: Historical and established RA cohorts have reported sex disparities in remission outcomes favoring male patients. The objective of the present study was to compare…
Abstract Number: 1428 • ACR Convergence 2022
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
Daniel Toro-Domínguez¹, José Linares-Blanco¹, Raúl López-Domínguez², Pilar S. López-Garrido², Georgina Galicia-Rosas¹, Pedro Carmona-Sáez² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Granada, Granada, Spain
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Timothy Wilson¹, Jacob Welch², Marie Feser², Elizabeth Bemis², Claudia Lugo², Gary S. Firestein³, Thomas F. Bumol⁴, Jill Norris⁵, V. Michael Holers⁶, Kevin D Deane⁷ and Kristen Demoruelle², ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California, San Diego, San Diego, CA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Aurora, CO, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
Abstract Number: 1436 • ACR Convergence 2022
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Mohaned Hameed¹, Sofia Exarchou¹, Anna Eberhard¹, Ankita Sharma¹, Ulf Bergström¹, Jon Einarsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Skåne University Hospital, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
Abstract Number: 0537 • ACR Convergence 2022
Neutrophil Extracellular Traps as a Biomarker to Predict Outcomes in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Farnoosh Naderinavi¹, Zahi Touma², Dafna Gladman³, Murray Urowitz⁴, Anna Konvalinka¹ and Joan Wither⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Neutrophil Extracellular Traps (NETs) have been implicated in Lupus Nephritis (LN) pathogenesis. SLE neutrophils release High Mobility Group Box-1 (HMGB1) protein, in turn, HMGB1…
Abstract Number: 1443 • ACR Convergence 2022
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…

« Previous Page
1
…
8
9
10
11
12
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].